Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.07 – $1.14
0% from low
Borrow rate
8.81%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $628.0K | $678.0K | $871.5K | $762.0K | $1.0M | $1.0M | $2.2M | $2.9M |
| Cost of revenue | $169.0K | $155.0K | $1.5M | $165.0K | $302.0K | $428.0K | $2.6M | $1.1M |
| Gross profit | $459.0K | $523.0K | −$678.0K | $597.0K | $711.0K | $613.0K | −$408.0K | $1.8M |
| Gross margin | 73.1% | 77.1% | -77.8% | 78.3% | 70.2% | 58.9% | -18.7% | 62.2% |
| R&D | $2.0M | $2.1M | $9.0M | $7.9M | $8.5M | $10.8M | $9.5M | $1.8M |
| Operating income | −$8.9M | −$10.9M | −$13.1M | −$13.7M | −$17.2M | −$24.2M | −$21.8M | −$15.1M |
| EBITDA | −$8.1M | −$9.8M | −$11.3M | −$12.2M | −$15.7M | −$24.4M | −$19.0M | −$13.0M |
| Net income | −$7.6M | −$8.9M | −$11.3M | −$11.6M | −$15.0M | −$21.7M | −$20.1M | −$14.2M |
| Net margin | -1203.2% | -1318.9% | -1300.5% | -1523.1% | -1481.9% | -2083.2% | -921.0% | -497.0% |
| EPS (diluted) | -0.79 | -0.66 | -0.69 | -0.65 | -0.67 | -0.88 | -0.77 | -0.48 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.05 | $-0.14–$0.00 | 1 |
| 2027 | $5M | $-0.04 | $-0.13–$0.00 | 1 |
| 2028 | $8M | $-0.01 | $-0.03–$0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ANPCY.
No tracked institution reports a position in ANPCY as of their last filing.
No one on the platform has traded ANPCY yet.
| $8M |
| — |
| LVCLFAlgorae Pharmaceuticals Limited | $0.01 | +17.90% | $16M | — |
| MDBIFTrivarX Limited | $0.00 | +0.00% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.7× sales vs its 22.6× historical median P/S.
Fair value ≈ $2.18 · price $0.07 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.